NCT00513851 2011-09-27Phase 1 Study of OSI-930 in Cancer PatientsAstellas Pharma IncPhase 1 Completed60 enrolled
NCT00603356 2011-09-27Phase I Study of OSI-930 and Erlotinib in Cancer TumorsAstellas Pharma IncPhase 1 Completed60 enrolled